RNAZ
TransCode Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.06
−4.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 52.7K | — | 534.9K | 516.7K | 98.6K |
| Gross Profit | (52.7K) | — | (534.9K) | (516.7K) | (98.6K) |
| Operating Expenses | |||||
| R&D Expense | 5.1B | 13.4M | 9.6M | 12.3M | 10.2M |
| SG&A Expense | 2.2B | 5.8M | 5.5M | 6.6M | 8.3M |
| General & Admin Expense | 2.2B | 5.8M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (7.3B) | 8.8M | — | — | — |
| Total Operating Expenses | 34.7M | 28.0M | 15.1M | 18.9M | 18.6M |
| Cost and Expenses | 34.7M | 28.0M | 15.7M | 19.4M | 18.7M |
| Operating Income (EBIT) | (34.7M) | (28.0M) | (15.7M) | (19.4M) | (18.7M) |
| Non-Operating | |||||
| Interest Income | 223.0K | 79.2K | 684.00 | 5.3K | 20.4K |
| Interest Expense | 6.5K | 6.6K | 26.8K | 55.9K | 17.6M |
| Net Interest Income | 216.5K | 72.6K | (26.1K) | (50.6K) | (17.5M) |
| Other Non-Op Income/Expense | (7.7M) | (6.5M) | (1.1M) | 872.4K | 1.1M |
| Non-Operating Income (excl Interest) | 7.7M | 6.4M | 1.1M | (928.3K) | (1.1M) |
| EBT (Pre-Tax Income) | (42.4M) | (34.4M) | (16.8M) | (18.5M) | (17.6M) |
| Income Tax Expense | 457.1K | 226.1K | — | — | — |
| Bottom Line | |||||
| Net Income | (42.8M) | (34.7M) | (16.8M) | (18.5M) | (17.6M) |
| Earnings from Cont. Ops | (42.8M) | (34.7M) | (16.8M) | (18.5M) | (17.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (46.3M) | (36.3M) | (16.8M) | (18.5M) | (17.6M) |
| Per Share | |||||
| Basic EPS | ($50.69) | ($52.59) | ($47.14) | ($3,453.65) | ($73,187.37) |
| Diluted EPS | ($50.69) | ($52.59) | ($47.14) | ($3,453.53) | ($1,080.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 937191 | 689713 | 356115 | 5424 | 16221 |
| Diluted Shares Outstanding | 937191 | 689713 | 356115 | 5424 | 16221 |
| Profitability Metrics | |||||
| EBITDA | (42.3M) | (34.3M) | (16.2M) | (18.0M) | (17.5M) |
| D&A | 97.4K | 114.2K | 534.9K | 516.7K | 98.6K |
| EBIT | (42.4M) | (34.4M) | (16.7M) | (18.5M) | (17.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026